Example: Heart Attack

Clinical Trials Sponsored by Puma Biotechnology, Inc.

Total 55 results

NCT05919108

Not yet recruiting

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Invasive Breast Lobular Carcinoma | Anatomic Stage I Breast Cancer | Anatomic Stage II Breast Cancer | Anatomic Stage III Breast Cancer
NCT05274048

Recruiting

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Gastric Cancer
NCT05252988

Recruiting

Trial to Evaluate Diarrhoea Discontinuations at 3 Cycles in Patients With Early-stage HER2+, HR+ Breast Cancer Treated With Neratinib Plus Loperamide Versus Neratinib Dose Escalation Plus Loperamide Administered as Needed Versus Neratinib Plus Loperamide Plus Colesevelam (DIANER)

HER2 Positive Breast Cancer | Hormone Receptor Positive | Early-stage Breast Cancer
NCT05243641

Recruiting

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

Breast Cancer | Metastatic Breast Cancer
NCT04886531

Recruiting

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers

Breast Cancer | HER2-positive Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer
NCT04502602

Recruiting

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE)

Ovarian Cancer | Advanced Solid Tumor
NCT03919292

Recruiting

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Solid Tumor, Adult
NCT03812393

Recruiting

Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2)

Triple Negative Breast Cancer | HER2-positive Breast Cancer | Early-stage Breast Cancer
NCT02977780

Recruiting

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Glioblastoma
NCT04901299

Withdrawn

Fulvestrant + Neratinib In Breast Cancer (HER2-Signal)

Metastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast Cancer
NCT04085315

Active, not recruiting

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Lung Cancer Metastatic | EGFR Gene Mutation
NCT04781374

Withdrawn

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma
NCT01494662

Active, not recruiting

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Breast Cancer
NCT03377387

Active, not recruiting

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Breast Cancer
NCT03289039

Terminated

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Breast Cancer
NCT04366713

Completed

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

HER2 Amplified Breast Cancer
NCT02236000

Completed

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Breast Cancer
NCT01953926

Completed

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
NCT03094052

Completed

Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

HER2-positive Breast Cancer | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma
NCT02400476

Completed

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Early Stage HER2+ Breast Cancer
NCT01670877

Completed

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Breast Neoplasms
NCT03457896

Active, not recruiting

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Metastatic Colorectal Cancer
NCT01008150

Completed

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Breast Cancer
NCT01808573

Completed

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

HER2+ Metastatic Breast Cancer (MBC)
NCT00878709

Completed

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET)

Breast Cancer
NCT03786107

Terminated

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Metastatic Cervical Cancer | Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
NCT01128842

Completed

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

Advanced Malignant Solid Tumors
NCT00768469

Completed

Study Evaluating Safety And Tolerability, Solid Tumor

Advanced Malignant Solid Tumors
NCT01111825

Completed

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Breast Cancer
NCT00838539

Completed

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Neoplasms | Malignant Carcinoma
NCT00146172

Completed

Study Evaluating HKI-272 in Tumors

Breast Neoplasms
NCT00397046

Completed

A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Tumors
NCT00741260

Completed

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Breast Cancer
NCT00915018

Completed

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer (NEFERTT)

Breast Cancer
NCT00300781

Completed

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Neoplasms | Breast Neoplasms
NCT00777101

Completed

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer
NCT00706030

Completed

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Breast Cancer | Advanced Malignant Solid Tumors
NCT00445458

Completed

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Breast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid Tumors
NCT00398567

Completed

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Advanced Breast Cancer
NCT01827267

Completed

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

HER2-mutant Non-Small Cell Lung Cancer
NCT00958724

Completed

Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

Advanced Malignant Solid Tumors
NCT00266877

Completed

Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms
NCT00366600

Completed

Study Evaluating HKI-272 Administered to Healthy Subjects

Healthy
NCT02334501

Completed

Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects

Healthy
NCT00860223

Completed

Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin

Healthy
NCT00498745

Completed

Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects

Healthy
NCT00814060

Completed

Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)

Healthy Subjects
NCT00550212

Completed

Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects

Healthy
NCT00864487

Completed

Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib

Healthy Subjects
NCT00708903

Completed

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

Breast Cancer

Clinical Trials Sponsored by Puma Biotechnology, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations